I suffered extensive fatigue that I had attributed to a COVID-19 infection. Then a lung culture found something called ...

The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD’s (Merck & ...

In addition to the poster sessions, Savara will host an Industry ... and innovation in the diagnosis and treatment of rare lung diseases. By presenting these findings, Savara Inc. contributes ...

University of Virginia School of Medicine scientists have discovered how severe COVID-19 can destroy immune cells' ability to repair the lungs, helping explain the lingering effects of long COVID.

interstitial lung disease. The symptoms that you may experience include a chronic dry cough, chest pain, and difficulty breathing during physical activity. Blood clots that block the arteries leading ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...

the loss of tolerance to which can result in autoimmune-mediated lung disease, has provided an explanation for the common pulmonary complications of autoimmune diseases. Systemic autoimmune ...